Healthcare Publications Regenerative Medicine Market

The global market for regenerative medicine is growing steadily. Factors that influence the
Regenerative Medicine Market are increasing advancement in healthcare technology,
increasing prevalence of chronic diseases and the rising growth in stem cell technology is
driving the growth of the market.
Globally the Regenerative Medicine Market is expected to grow at the rate of about 25.4%
from 2016 to 2022.
The demand for biologically derived materials for regenerative medicine is currently high
due to its efficiency over other naturally derived materials. During the surgical procedures,
synthetic materials are more preferred as they provide better outcome. Increase in demand
for material reengineering and cell biology with the recent progress in the design of
synthetic materials have led to the use of hydrogel in the formation of tissue-engineered
scaffolds.
Furthermore, the increasing incidence of degenerative diseases and shortage of organs for
transplantation are expected to boost the growth of the market. The prominent potential of
regenerative medicine to replace, repair, and regenerate damaged tissues and organs has
boosted the market growth. Moreover, utilization of nanomaterials in wound care, drug
delivery, and immunomodulation has spurred the growth avenues for the regenerative
medicines market. However, stringent regulatory barriers and high cost of the treatment are
likely to hinder the market growth
Numerous government bodies are encouraging the growing Regenerative Medicine Market.
For instance, National Institutes of Health (NIH) supports scientific research community
through NIH Regenerative Medicine Program, International SC Research, State Initiatives
for Stem Cell Research, NIH SC Unit, NIH SC Libraries & Projects, and NIH SC Translation
Laboratory. However, identifying the potential clinical applications in countries such as U.S.,
UK, China, and Japan have introduced changes in their regulatory policies to encourage
research. Thus, the industry is projected to reflect accelerated growth over the forecast
period.
The Global Regenerative Medicine Market is observed to be highly competitive and
fragmented. The key entities are perceived to have high investments in development of
regenerative therapies to capture the untapped potential by innovating novel therapies to
meet the demand for unmet clinical needs.
In addition, key players are witnessed to focus on oncology & age-related degenerative
disorders to compete in the market. Thereby, the industry witnesses a strong pipeline of
products in clinical trials, which eventually are expected to drive revenue generation.
Organogenesis Inc. (U.S.), Osiris Therapeutics, Inc. (U.S.), Vericel Corporation (U.S.),
Stryker Corporation (U.S.), NuVasive, Inc. (U.S.), Medtronic (Ireland), Acelity (KCI
Concepts) (U.S.), Integra LifeSciences (U.S.), Cook Biotech Inc. (U.S.), C.R. Bard (U.S.),
RTI surgical (U.S.), Baxter International, Inc. (U.S.), Advanced Cell Technology (U.S.),
CryoLife (U.S.), Sanofi (France), BioMimetic Therapeutics (U.S.), StemCells Inc. (U.S.),
LifeCell Kinetic Concepts (U.S.) and others are some of the prominent players at the
forefront of competition in the Global Regenerative Medicine Market and are profiled in
MRFR Analysis.
Sample Copy Access @ https://www.marketresearchfuture.com/sample_request/2220 .
Industry Updates
October, 2017 Advanced Medical Solutions Group and Organogenesis Inc. enter into patent
out-licensing agreement. The companies have agreed on the US patent on the collagen-
based wound dressing containing Polyhexamethylene Biguanide
July, 2017 Baxter International Inc., a global medical products company announced the
acquisition of Claris Injectables Limited. The acquisition is expected to broaden Baxter’s
presence in the generic pharmaceuticals market and will boost the supply of essential
medicines to the customers.
March, 2017 Organogenesis Inc. has acquired NuTech Medical. The newly-formed company
has expanded product portfolio for the wound care and surgical biologics markets.